Bracco Diagnostics
RELATED CONTENT
MultiHance is the highest relaxivity gadolinium-based MRI contrast agent approved for use in the US for MRI of the CNS. ...
November 06, 2008 
In this retrospectively gated full thoracic CT study, the examination was performed using the LightSpeed VCT 64 system with 0.625 mm detector collimation, retrospective cardiac gating and mono-sector reconstruction. The patient received three 5 mg injections of Metoprolol intravenously for cardiac rate control. Heart rate during acquisition was 64 to 65 BPM.
October 02, 2008 
Over the past year, headlines across industry and consumer media have highlighted FDA warnings on the dangers of gadolinium-based contrast agents. To date, it has become common knowledge and a FDA black box warning that gadolinium-based agents run the risk of causing Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy (NSF/NFD).
October 02, 2008 
This case is a routine coronary CTA with the focus on the coronary arteries. The patient was a middle-aged male with a family history of coronary artery disease, moderate risk profile and atypical chest pain. The EKG did not indicate myocardial ischemia and there was no enzyme leak.
October 02, 2008 
Gastrografin (diatrizoate meglumine and diatrizoate sodium solution USP) is a palatable lemon-flavored, water-soluble iodinated radiopaque contrast medium for oral or rectal administration used for radiographic examination of segments of the gastrointestinal tract and as an adjunct to contrast enhancement in CT of the torso.
September 30, 2008 
The contrast agent Isovue, according to its manufacturer, is said to be a safe and effective nonionic contrast medium well established with U.S. clinical experience since 1986. Worldwide, more than 250 million doses of iopamidol have been administered.
September 30, 2008 
MultiHance (gadobenate dimeglumine) is indicated for intravenous use in MRI of the CNS in adults to visualize lesions ...
September 30, 2008 Bracco's Isovue (iopamidol injection) X-ray/CT contrast is reportedly a safe and effective nonionic contrast agent, which is well established with U.S. clinical experience since 1986. Worldwide, more than 250 million doses of iopamidol have been administered, the company said.
August 19, 2008 August 4, 2008 - There is no statistically significant difference between iopamidol-370 (Isovue-370) and iodixanol-320 ...
August 05, 2008 June 18, 2008 – Bracco Diagnostics showcased its Cardiac PET Perfusion Imaging with CardioGen-82, a Rubidium Rb 82 ...
June 17, 2008